J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout

Posted inBiotechnology

Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.